Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144780 · ClinicalTrials.gov registry record
Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 10
- Enrollment target
NCT01144780: Clinical Trial study, sponsored by Stanford University.
NCT01144780 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01144780 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The objective of this study is to better understand the underlying pathogenetic mechanisms of myeloproliferative disorders (MPDs). We will collect peripheral blood samples from MPD patients and utilize multiparameter phospho-specific flow cytometry to investigate dysregulated signaling in blood cells from these patients. This will provide deeper insights into the pathogenesis of MPDs and may lead to the identification of novel targets for therapeutic intervention.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144780
The ClinicalTrials.gov registry entry for NCT01144780 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01144780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01144780 about?
NCT01144780 is a clinical study titled "Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry". The objective of this study is to better understand the underlying pathogenetic mechanisms of myeloproliferative disorders (MPDs). We will collect peripheral blood samples from MPD patients and utilize multiparameter phospho-specific flow cytometry to investigate dysregulated signaling in blood cell...
What is the current status of trial NCT01144780?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2009-09. Estimated completion is 2012-06.
Who is sponsoring clinical trial NCT01144780?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.